Flamingo announces agreement with CUA Health
Flamingo AI Limited (ASX:FGO) informed the market this morning that it has signed a binding commercial term sheet with CUA Health Ltd, a subsidiary of Credit Union Australia, for a paid trial of FGO’s Cognitive Virtual Sales Assistant ROSIE.
During the three months spanning the live evaluation trial, CUA’s customers as well as CUA Health members will interact with ROSIE in a similar arrangement to FGO’s pre-existing live evaluation trials with Australian companies DirectMoney and AMP.
Flamingo’s CEO, Dr Catriona Wallace, commented on today’s announcement.
“We are extremely pleased to be working with CUA Health on the deployment of a Virtual Assistant to support their customers purchasing Health Insurance.
“We believe that AI and Machine Learning technology such as Flamingo provides will be very relevant to the health insurance sector,” she said.
National Sales & Marketing Manager at CUA Health, Richard Martin said, “This is an exciting collaboration opportunity that has arisen from our sponsorship of the Stone & Chalk fintech hub.
“We’re keen to test what opportunities there are for this technology to supplement our personalised interactions with members, potentially managing many of the most common health insurance inquiries coming in through our digital sales channels.”
It should be noted that it is early stages in this partnership and investors should seek professional financial advice for further information if considering this stock for their portfolio.
Earlier this week, the company released an update regarding live evaluation trials of ROSIE currently underway with three of FGO’s clients in the US and Australia.
It also reported that feedback from client companies has so far has been highly positive, and the company is in discussions with several clients relating to a shift from live evaluation to Monthly Recurring Revenue arrangements.
FGO continues to build its strong sales pipeline across all three regions. It continues its supportive partnership with the US-based Clarion Group, which has historically been an excellent source of sale and contract leads for FGO.
Wallace conducted several sales meetings with Clarion representatives during a trip to the US this month, with the company also announcing it would be expanding its sales teams in both the US and Asia Pacific.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.